Gut microbiota remodeling: A promising therapeutic strategy to confront hyperuricemia and gout
Z Wang, Y Li, W Liao, J Huang, Y Liu, Z Li… - Frontiers in cellular and …, 2022 - frontiersin.org
The incidence of hyperuricemia (HUA) and gout continuously increases and has become a
major public health problem. The gut microbiota, which colonizes the human intestine, has a …
major public health problem. The gut microbiota, which colonizes the human intestine, has a …
The potential of probiotics in the amelioration of hyperuricemia
Hyperuricemia is a common disease caused by metabolic disorders or the excessive intake
of high-purine foods. Persistent hyperuricemia in extreme cases induces gout, and …
of high-purine foods. Persistent hyperuricemia in extreme cases induces gout, and …
Unveiling the therapeutic potential of exogenous β-hydroxybutyrate for chronic colitis in rats: Novel insights on autophagy, apoptosis, and pyroptosis
R Abdelhady, S Saber… - Frontiers in …, 2023 - frontiersin.org
Ulcerative colitis (UC) is a chronic relapsing inflammatory disease of the colorectal area that
demonstrates a dramatically increasing incidence worldwide. This study provides novel …
demonstrates a dramatically increasing incidence worldwide. This study provides novel …
[HTML][HTML] The dynamic interplay between AMPK/NFκB signaling and NLRP3 is a new therapeutic target in inflammation: Emerging role of dapagliflozin in overcoming …
Acute lung injury (ALI) is one the most common causes of morbidity and mortality in critically
ill patients. In this study, we examined for first time the role of dapagliflozin (DPGZ) in …
ill patients. In this study, we examined for first time the role of dapagliflozin (DPGZ) in …
[HTML][HTML] Modulating the HSP90 control over NFκB/NLRP3/Caspase-1 axis is a new therapeutic target in the management of liver fibrosis: insights into the role of TAS …
Aberrant activation of the NLRP3 inflammasome is recognized to induce a chronic
inflammatory response in the liver, ultimately leading to hepatic fibrosis. HSP90 is suggested …
inflammatory response in the liver, ultimately leading to hepatic fibrosis. HSP90 is suggested …
[HTML][HTML] Innovative challenge for the inhibition of hepatocellular carcinoma progression by combined targeting of HSP90 and STAT3/HIF-1α signaling
Hepatocellular carcinoma (HCC) is the third foremost cause of cancer-related deaths. HCC
has a very bad prognosis because it is asymptomatic in the early stages, resulting in a late …
has a very bad prognosis because it is asymptomatic in the early stages, resulting in a late …
[HTML][HTML] Ganetespib (STA-9090) augments sorafenib efficacy via necroptosis induction in hepatocellular carcinoma: Implications from preclinical data for a novel …
Sorafenib, a multikinase inhibitor, is a first-line treatment for advanced hepatocellular
carcinoma, but its long-term effectiveness is limited by the emergence of resistance …
carcinoma, but its long-term effectiveness is limited by the emergence of resistance …
[HTML][HTML] Canagliflozin-loaded chitosan-hyaluronic acid microspheres modulate AMPK/NF-κB/NLRP3 axis: A new paradigm in the rectal therapy of ulcerative colitis
Ulcerative colitis is an idiopathic disease that is widely incident worldwide. Canagliflozin,
antidiabetic agent, exhibited significant anti-inflammatory effects in a variety of animal …
antidiabetic agent, exhibited significant anti-inflammatory effects in a variety of animal …
Interference with the AMPKα/mTOR/NLRP3 signaling and the IL-23/IL-17 axis effectively protects against the dextran sulfate sodium intoxication in rats: a new …
ME Youssef, EE Abd El-Fattah… - Frontiers in …, 2021 - frontiersin.org
Empagliflozin and metformin are widely used for the treatment of type 2 diabetes. These
drugs showed marked anti-inflammatory effects in different animal models via enhancing …
drugs showed marked anti-inflammatory effects in different animal models via enhancing …
Ambroxol, a mucolytic agent, boosts HO‐1, suppresses NF‐κB, and decreases the susceptibility of the inflamed rat colon to apoptosis: A new treatment option for …
Ulcerative colitis (UC) is a chronic inflammatory bowel disease of unknown etiology that
increases the risk of developing colorectal cancer and imposes a lifelong healthcare burden …
increases the risk of developing colorectal cancer and imposes a lifelong healthcare burden …